Telemetry Investments, L.L.C. Gain Therapeutics, Inc. Transaction History
Telemetry Investments, L.L.C.
- $63.3 Million
- Q4 2022
A detailed history of Telemetry Investments, L.L.C. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Telemetry Investments, L.L.C. holds 123,000 shares of GANX stock, worth $285,360. This represents 0.61% of its overall portfolio holdings.
Number of Shares
123,000
Previous 150,000
18.0%
Holding current value
$285,360
Previous $489,000
21.27%
% of portfolio
0.61%
Previous 0.63%
Shares
7 transactions
Others Institutions Holding GANX
# of Institutions
30Shares Held
2.69MCall Options Held
5.7KPut Options Held
10.6K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.37 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.31 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$620,4160.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$410,8140.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny158KShares$366,9190.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $27.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...